| Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Ting L.S., Benoit-Biancamano M.O., Bernard O., Riggs K.W., Guillemette C., Ensom M.H.
Pharmacotherapy 30:1097-1108(2010) · Mapped (6) |
| Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. Bains O.S., Grigliatti T.A., Reid R.E., Riggs K.W.
J. Pharmacol. Exp. Ther. 335:533-545(2010) |
| The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone. Takahashi R.H., Grigliatti T.A., Reid R.E., Riggs K.W.
J. Pharmacol. Exp. Ther. 329:1032-1039(2009) · Mapped (3) |
| Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Bains O.S., Karkling M.J., Grigliatti T.A., Reid R.E., Riggs K.W.
Drug Metab. Dispos. 37:1107-1114(2009) · Mapped (2) |
| Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Bains O.S., Takahashi R.H., Pfeifer T.A., Grigliatti T.A., Reid R.E., Riggs K.W.
Drug Metab. Dispos. 36:904-910(2008) · UniProtKB (1) |
